Scientific Director/ AbbVie

Dr. Jack SH Chen is a scientist in cancer research by training with 10+ years of drug R & D experience in biopharmaceutical industries. He is currently a Scientific Director for Precision Medicine at AbbVie (a Top 5 global pharma company by revenue, a previous pharmaceutical unit from Abbott). He oversees a group of PhD scientists to develop translational oncology strategy and discover biomarkers of response to antibody-drug-conjugates and immunotherapy programs from preclinical to Ph1/2 clinical stages. Prior to this, he was a Senior Principal Scientist and discovery team leader in oncology R & D at Pfizer, driving programs from target validation to Phase 1 clinical trials. Prior to this, he previously worked at OncoMed and Eli Lilly for cancer targeted therapies and immunotherapies. He obtained his Ph.D. from Johns Hopkins University and M.S./B.S. from National Taiwan University.

陳博士是癌症研究科學家，擁有十餘年生技製藥產業藥物研發經驗。他目前擔任艾伯維大藥廠（全球收入排名前五的製藥公司，前身為亞培大藥廠的製藥部門）的精準醫學科學總監，帶領一群博士科學家研發抗體-藥物偶聯物和免疫治療項目從臨床前到Ph1/2臨床階段的轉化腫瘤學策略及找尋對新藥療效的的生物標記。在此之前，他曾擔任輝瑞公司的高級首席科學家和研發團隊負責人，推動計畫從標靶驗證到一期臨床試驗的開展。在此之前，他曾在OncoMed和禮來大藥廠工作，負責癌症標靶治療和免疫療法的研究。他擁有約翰霍普金斯大學博士學位和台灣大學碩士/學士學位。